Vancouver, British Columbia — January 15, 2026 — Leads & Copy — BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) has achieved a significant milestone in its long-term investment in integrating artificial intelligence and machine learning into metabolomic profiling.
The healthcare investment community is focused on the transformative power of AI at the J.P. Morgan Healthcare Conference. BioMark received notification this week that its research regarding a machine learning-driven predictive model for lung cancer detection has been accepted for publication in Frontiers in Oncology.
The article, titled “Translational impact of machine learning-driven predictive modeling with pathway-based plasma metabolomic biomarkers for lung cancer detection,” represents a successful realization of BioMark’s strategy to utilize advanced computational tools to enhance diagnostic precision. This validates the company’s past capital allocation toward sophisticated AI infrastructure and confirms the scientific rigor of its metabolic pathway analysis.
BioMark has demonstrated a more comprehensive way to interpret the metabolic signatures of early-stage lung cancer by moving beyond traditional biomarker identification and utilizing pathway-level data.
The research was made possible through a strategic collaboration with Dr. Maria Vaida and her team at Harrisburg University of Science and Technology. The work led by Dr. Vaida has been recognized for its high quality and its significant contribution to the field of oncology. The publication describes the use of pathway-based features from the Human Metabolome Database (HMDB) and explores the mechanistic drivers of cancer through interpretability tools such as SHAP analysis.
This methodological approach allows for a deeper understanding of how specific metabolic pathways, such as those involved in nutrient processing and tumor growth, contribute to diagnostic models. The partnership with Harrisburg University has been instrumental in bridging the gap between complex data science and clinical application, ensuring that BioMark’s technological foundation is built upon peer-reviewed, world-class scientific inquiry.
According to Rashid Ahmed Bux, President and CEO of BioMark, the acceptance of their work in Frontiers in Oncology is a pivotal moment for BioMark, as it provides third-party validation of the investments they have made in AI and machine learning over the past several years.
Bux added that at a time when the healthcare industry is increasingly looking for ‘proof of concept’ in AI applications, this publication confirms that their collaborative work with Harrisburg University meets the highest standards of scientific excellence. He stated that they have successfully demonstrated that integrating machine learning with metabolomics is not just a theoretical pursuit, but a validated methodology that provides deep insights into the metabolic complexities of lung cancer.
The full paper is expected to be published later this month and will be made available through BioMark’s website. This milestone reinforces the company’s commitment to scientific transparency and its position at the intersection of oncology, metabolomics, and advanced data science.
BioMark Diagnostics Inc. is a developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine learning algorithms. The company’s technology utilizes a blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. BioMark Diagnostics Inc. is committed to developing innovative and accessible diagnostic solutions to address unmet medical needs in oncology.
Rashid Ahmed Bux is the President & CEO of BioMark Diagnostics Inc. and can be reached at Tel. 604-370-0779 or Email: info@biomarkdiagnostics.com
Source: BioMark Diagnostics Inc.
